"In November 2024, preliminary results of CASP16 showed AlphaFold 3-based models did not significantly outperform older methods for predicting protein-ligand interactions. The top performing models in the CASP16 Pose Prediction for Pharma Targets section were ClusPro[13] and CoDock[14] utilizing AlphaFold 2 based predictions, human visual inspection, and manual adjustments.[15]
In April 2025 Isomorphic Labs raised $600 Million in its first ever external funding round, led by Thrive Capital.[16][17]"
Would like more details technically on their approach. Is it a neuro-symbolic approach, do they do something beyond just scaling, or some other architecture breakthrough, but alas drug discovery must remain proprietary. Thank gods for capitalism!
In April 2025 Isomorphic Labs raised $600 Million in its first ever external funding round, led by Thrive Capital.[16][17]"
https://en.wikipedia.org/wiki/Isomorphic_Labs